Ukihide Tateishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ukihide Tateishi has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Tomio Inoue
Department of Radiology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
16 shared publicationsTakashi Terauchi
National Cancer Center
10 shared publicationsKazuya Shizukuishi
From the Departments of *Radiology, and †Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan
7 shared publications- Tomio Inoue
Department of Oral Physiology, Showa University School of Dentistry, Tokyo, Japan
5 shared publications Tomohiro Yoneyama
Department of Radiology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
5 shared publicationsYuji Nishiyama
Yokohama City Univ, Grad Sch Med, Dept Radiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
4 shared publications
Latest Publications
- Open Access
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Radiology
- Vol. 8 (8) , 743-749
Tumor characteristics of ductal carcinomain situof breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study
Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Radiology
- Vol. 8 (8) , 743-749
Open AccessTumor characteristics of ductal carcinomain situof breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study
Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study
- 1 October 2014
- Published by Elsevier in European Journal of Radiology
- Vol. 83 (10) , 1734-1739
Staging accuracy of pancreatic cancer: Comparison between non-contrast-enhanced and contrast-enhanced PET/CT
- 1 October 2014
- Published by Elsevier in European Journal of Radiology
- Vol. 83 (10) , 1734-1739
Staging accuracy of pancreatic cancer: Comparison between non-contrast-enhanced and contrast-enhanced PET/CT
- Open Access
- 2 June 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 390
The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the RCC metastasis is located. We previously reported that the FDG accumulation assessed by FDG PET/CT, was a powerful index for evaluating the biological response to TKI. In this study we investigated the differences in FDG accumulation and the response to TKI as assessed by FDG PET/CT among various organs where RCC were located. A total of 48 patients with advanced RCC treated with a TKI (25 with sunitinib and 23 with sorafenib) were evaluated by FDG PET/CT before and at 1 month after a TKI treatment initiation. The maximum standardized uptake value (SUVmax) of all RCC lesions were measured and analyzed. We evaluated 190 RCC lesions. The pretreatment SUVmax values (mean ± SD) were as follows: in the 49 lung metastases, 4.1 ± 3.3; in the 40 bone metastases, 5.4 ± 1.6; in the 37 lymph node metastases, 6.7 ± 2.7; in the 29 abdominal parenchymal organ metastases, 6.6 ± 2.7; in the 26 muscle or soft tissue metastases, 4.4 ± 2.6; and in the nine primary lesions, 8.9 ± 3.9. Significant differences in the SUVmax were revealed between metastases and primary lesions (p = 0.006) and between lung metastases and non-lung metastases (p < 0.001). The SUVmax change ratios at 1 month after TKI treatment started were -14.2 ± 48.4% in the lung metastases, -10.4 ± 23.3% in the bone metastases, -9.3 ± 47.4% in the lymph node metastases, -24.5 ± 41.7% in the abdominal parenchymal organ metastases, -10.6 ± 47.4% in the muscle or soft tissue metastases, and -24.2 ± 18.3% in the primary lesions. There was no significant difference among the organs (p = 0.531). The decrease ratio of FDG accumulation of RCC lesions evaluated by PET/CT at 1 month after TKI treatment initiation was not influenced by the organs where the RCC metastasis was located. This result suggests that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site.
- 2 June 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 390
Open AccessThe early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the RCC metastasis is located. We previously reported that the FDG accumulation assessed by FDG PET/CT, was a powerful index for evaluating the biological response to TKI. In this study we investigated the differences in FDG accumulation and the response to TKI as assessed by FDG PET/CT among various organs where RCC were located. A total of 48 patients with advanced RCC treated with a TKI (25 with sunitinib and 23 with sorafenib) were evaluated by FDG PET/CT before and at 1 month after a TKI treatment initiation. The maximum standardized uptake value (SUVmax) of all RCC lesions were measured and analyzed. We evaluated 190 RCC lesions. The pretreatment SUVmax values (mean ± SD) were as follows: in the 49 lung metastases, 4.1 ± 3.3; in the 40 bone metastases, 5.4 ± 1.6; in the 37 lymph node metastases, 6.7 ± 2.7; in the 29 abdominal parenchymal organ metastases, 6.6 ± 2.7; in the 26 muscle or soft tissue metastases, 4.4 ± 2.6; and in the nine primary lesions, 8.9 ± 3.9. Significant differences in the SUVmax were revealed between metastases and primary lesions (p = 0.006) and between lung metastases and non-lung metastases (p < 0.001). The SUVmax change ratios at 1 month after TKI treatment started were -14.2 ± 48.4% in the lung metastases, -10.4 ± 23.3% in the bone metastases, -9.3 ± 47.4% in the lymph node metastases, -24.5 ± 41.7% in the abdominal parenchymal organ metastases, -10.6 ± 47.4% in the muscle or soft tissue metastases, and -24.2 ± 18.3% in the primary lesions. There was no significant difference among the organs (p = 0.531). The decrease ratio of FDG accumulation of RCC lesions evaluated by PET/CT at 1 month after TKI treatment initiation was not influenced by the organs where the RCC metastasis was located. This result suggests that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site.
- 10 April 2014
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 41 (7) , 1419-1427
Tumor hypoxia and microscopic diffusion capacity in brain tumors: A comparison of 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging
The aim of this study was to clarify the relationship between tumor hypoxia and microscopic diffusion capacity in primary brain tumors using 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) (62Cu-ATSM) PET/CT and diffusion-weighted MR imaging (DWI). This study was approved by the institutional human research committee and was HIPAA compliant, and informed consent was obtained from all patients. 62Cu-ATSM PET/CT and DWI were performed in a total of 40 primary brain tumors of 34 patients with low grade glioma (LGG, n = 13), glioblastoma (GBM, n = 20), and primary central nervous system lymphoma (PCNSL, n = 7). 62Cu-ATSM PET/CT parameters and apparent diffusion coefficient (ADC) obtained by DWI were compared. High intensity signals by 62Cu-ATSM PET/CT and DWI in patients with GBM and PCNSL, and low intensity signals in LGG patients were observed. An inverse correlation was found between maximum SUV (SUVmax) and minimum ADC (ADCmin) (r = −0.583, p < 0.0001), and between tumor/brain ratio (T/Bratio) and ADCmin for all tumors (r = −0.532, p < 0.0001). Both SUVmax and T/Bratio in GBM were higher than LGG (p < 0.0001 and p < 0.0001), and those in PCNSL were also higher than GBM (p = 0.033 and p = 0.044). The ADCmin was lower in GBM (p = 0.011) and PCNSL (p = 0.01) than in LGG, while no significant difference was found between GBM and PCNSL (p = 0.90). Tumor hypoxia assessed by 62Cu-ATSM PET/CT correlated with microscopic diffusion capacity obtained by DWI in brain tumors. Both 62Cu-ATSM PET/CT and DWI were considered feasible imaging methods for grading glioma. However, 62Cu-ATSM PET/CT provided additional diagnostic information to differentiate between GBM and PCNSL.
- 10 April 2014
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 41 (7) , 1419-1427
Tumor hypoxia and microscopic diffusion capacity in brain tumors: A comparison of 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging
The aim of this study was to clarify the relationship between tumor hypoxia and microscopic diffusion capacity in primary brain tumors using 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) (62Cu-ATSM) PET/CT and diffusion-weighted MR imaging (DWI). This study was approved by the institutional human research committee and was HIPAA compliant, and informed consent was obtained from all patients. 62Cu-ATSM PET/CT and DWI were performed in a total of 40 primary brain tumors of 34 patients with low grade glioma (LGG, n = 13), glioblastoma (GBM, n = 20), and primary central nervous system lymphoma (PCNSL, n = 7). 62Cu-ATSM PET/CT parameters and apparent diffusion coefficient (ADC) obtained by DWI were compared. High intensity signals by 62Cu-ATSM PET/CT and DWI in patients with GBM and PCNSL, and low intensity signals in LGG patients were observed. An inverse correlation was found between maximum SUV (SUVmax) and minimum ADC (ADCmin) (r = −0.583, p < 0.0001), and between tumor/brain ratio (T/Bratio) and ADCmin for all tumors (r = −0.532, p < 0.0001). Both SUVmax and T/Bratio in GBM were higher than LGG (p < 0.0001 and p < 0.0001), and those in PCNSL were also higher than GBM (p = 0.033 and p = 0.044). The ADCmin was lower in GBM (p = 0.011) and PCNSL (p = 0.01) than in LGG, while no significant difference was found between GBM and PCNSL (p = 0.90). Tumor hypoxia assessed by 62Cu-ATSM PET/CT correlated with microscopic diffusion capacity obtained by DWI in brain tumors. Both 62Cu-ATSM PET/CT and DWI were considered feasible imaging methods for grading glioma. However, 62Cu-ATSM PET/CT provided additional diagnostic information to differentiate between GBM and PCNSL.
- 21 January 2014
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 32 (3) , 155-163
Correlation of metabolic tumor volume and 11C-choline uptake with the pathology of prostate cancer: evaluation by use of simultaneously recorded MR and PET images
This study was conducted to assess the relationship between 11C-choline uptake and pathologic findings obtained by combined use of magnetic resonance (MR) and positron emission tomography (PET) imaging of patients with prostate cancer. We retrospectively evaluated 69 patients with prostate cancer who underwent 11C-choline PET-CT and magnetic resonance imaging before radical prostatectomy. Combined MR–PET images were acquired to obtain precise anatomic information. The maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were compared with pathologic findings from resected specimens as the reference standard. The mean and standard deviation of tumor SUVmax and MTV were 3.9 ± 1.8 and 12.9 ± 16.4, respectively. Tumors with high MTV (≧8.2) were more likely to be admixed with prostatic intraepithelial neoplasia (PIN) (p < 0.0001) or hyperplasia (p < 0.0001) in the background than those without these findings. Multiple regression analysis also revealed that the presence of hyperplasia (OR; 4.25, 95 % CI 1.25–14.4, p = 0.02) and PIN (OR; 9.22, 95 % CI 2.60–32.7, p = 0.001) were associated with tumors with high MTV. We have demonstrated, by pathologic evaluation of patients with prostate cancer, that 11C-choline uptake volume is greater for prostate cancer admixed with PIN and hyperplasia than that without.
- 21 January 2014
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 32 (3) , 155-163
Correlation of metabolic tumor volume and 11C-choline uptake with the pathology of prostate cancer: evaluation by use of simultaneously recorded MR and PET images
This study was conducted to assess the relationship between 11C-choline uptake and pathologic findings obtained by combined use of magnetic resonance (MR) and positron emission tomography (PET) imaging of patients with prostate cancer. We retrospectively evaluated 69 patients with prostate cancer who underwent 11C-choline PET-CT and magnetic resonance imaging before radical prostatectomy. Combined MR–PET images were acquired to obtain precise anatomic information. The maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were compared with pathologic findings from resected specimens as the reference standard. The mean and standard deviation of tumor SUVmax and MTV were 3.9 ± 1.8 and 12.9 ± 16.4, respectively. Tumors with high MTV (≧8.2) were more likely to be admixed with prostatic intraepithelial neoplasia (PIN) (p < 0.0001) or hyperplasia (p < 0.0001) in the background than those without these findings. Multiple regression analysis also revealed that the presence of hyperplasia (OR; 4.25, 95 % CI 1.25–14.4, p = 0.02) and PIN (OR; 9.22, 95 % CI 2.60–32.7, p = 0.001) were associated with tumors with high MTV. We have demonstrated, by pathologic evaluation of patients with prostate cancer, that 11C-choline uptake volume is greater for prostate cancer admixed with PIN and hyperplasia than that without.
- 25 September 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 98 (4) , 398-405
PET/CT in malignant lymphoma: basic information, clinical application, and proposal
Coregistered fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) provides functional and morphologic data useful for the management of lymphoma. PET/CT is a promising tool in initial staging/re-staging, monitoring post-treatment recurrence/exacerbation, and evaluating prognosis at mid-treatment use [interim PET/CT (iPET/CT)]. Many multicenter studies are currently underway to investigate the effectiveness and safety of stratified treatment protocols using iPET/CT. Thus, the establishment of a system focusing on standardization of image quality through established protocols for scanning or quality control (QC) of the acquired data and organization of a core laboratory facility to promote standardization would be beneficial. Uniformity of image quality across multiple institutions can be guaranteed through optimization of imaging conditions and appropriate QC of PET/CT scanners to ensure standardization. Further research is required to ensure the standardization of PET/CT protocols used in the management of malignant lymphoma.
- 25 September 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 98 (4) , 398-405
PET/CT in malignant lymphoma: basic information, clinical application, and proposal
Coregistered fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) provides functional and morphologic data useful for the management of lymphoma. PET/CT is a promising tool in initial staging/re-staging, monitoring post-treatment recurrence/exacerbation, and evaluating prognosis at mid-treatment use [interim PET/CT (iPET/CT)]. Many multicenter studies are currently underway to investigate the effectiveness and safety of stratified treatment protocols using iPET/CT. Thus, the establishment of a system focusing on standardization of image quality through established protocols for scanning or quality control (QC) of the acquired data and organization of a core laboratory facility to promote standardization would be beneficial. Uniformity of image quality across multiple institutions can be guaranteed through optimization of imaging conditions and appropriate QC of PET/CT scanners to ensure standardization. Further research is required to ensure the standardization of PET/CT protocols used in the management of malignant lymphoma.
- 1 March 2013
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 38 (3) , e125-e131
18F-Fluoride PET/CT Allows Detection of Hyperostosis and Osseous Involvement in Meningioma
Purpose The present study was conducted to assess the diagnostic performance of 18F-fluoride PET/CT in evaluating hyperostosis and osseous involvement in patients with meningioma. Patients and Methods Thirty-four patients with meningioma (mean age, 61 years) underwent 18F-fluoride PET/CT before surgery. In 24 patients (71%), 18F-FDG PET/CT was also given before surgery, and the results were compared. The images were reviewed by 2 board-certified nuclear medicine specialists who were unaware of any clinical information and a consensus was reached. Uptake patterns and measurements of tracers were compared with pathological findings from resected specimens, with hyperostosis and osseous involvement as the reference standard. Results There were 27 grade I tumors (79%) and 7 grade II tumors (21%). The primary tumor focus was identified in each patient using both 18F-fluoroide PET/CT and 18F-FDG PET/CT, but there were no significant correlations in the degree of uptake between the 2 tracers. The SUVmax, SUVmax corrected for lean body mass (SULmax), and tumor metabolic volume (TMV) for 18F-fluoride and 18F-FDG were greater in grade II tumors than in grade I tumors. Hyperostosis and osseous involvement was identified in 12 tumors (38%). The SUVmax, SULmax, and TMV of tumors visualized with 18F-fluoride PET/CT were greater in tumors with hyperostosis and osseous involvement than in those without (P = 0.005, P = 0.003, and P = 0.006, respectively). In contrast, the SUVmax, SULmax, and TMV of tumors visualized with 18F-FDG PET/CT were similar regardless of hyperostosis or osseous involvement. Conclusions 18F-fluoride PET/CT may improve detection of hyperostosis and osseous involvement in patients with meningioma.
- 1 March 2013
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 38 (3) , e125-e131
18F-Fluoride PET/CT Allows Detection of Hyperostosis and Osseous Involvement in Meningioma
Purpose The present study was conducted to assess the diagnostic performance of 18F-fluoride PET/CT in evaluating hyperostosis and osseous involvement in patients with meningioma. Patients and Methods Thirty-four patients with meningioma (mean age, 61 years) underwent 18F-fluoride PET/CT before surgery. In 24 patients (71%), 18F-FDG PET/CT was also given before surgery, and the results were compared. The images were reviewed by 2 board-certified nuclear medicine specialists who were unaware of any clinical information and a consensus was reached. Uptake patterns and measurements of tracers were compared with pathological findings from resected specimens, with hyperostosis and osseous involvement as the reference standard. Results There were 27 grade I tumors (79%) and 7 grade II tumors (21%). The primary tumor focus was identified in each patient using both 18F-fluoroide PET/CT and 18F-FDG PET/CT, but there were no significant correlations in the degree of uptake between the 2 tracers. The SUVmax, SUVmax corrected for lean body mass (SULmax), and tumor metabolic volume (TMV) for 18F-fluoride and 18F-FDG were greater in grade II tumors than in grade I tumors. Hyperostosis and osseous involvement was identified in 12 tumors (38%). The SUVmax, SULmax, and TMV of tumors visualized with 18F-fluoride PET/CT were greater in tumors with hyperostosis and osseous involvement than in those without (P = 0.005, P = 0.003, and P = 0.006, respectively). In contrast, the SUVmax, SULmax, and TMV of tumors visualized with 18F-FDG PET/CT were similar regardless of hyperostosis or osseous involvement. Conclusions 18F-fluoride PET/CT may improve detection of hyperostosis and osseous involvement in patients with meningioma.
- 1 January 2013
- Published by Elsevier in European Journal of Radiology
- Vol. 82 (1) , 69-74
Role of respiratory-gated PET/CT for pancreatic tumors: A preliminary result
- 1 January 2013
- Published by Elsevier in European Journal of Radiology
- Vol. 82 (1) , 69-74
Role of respiratory-gated PET/CT for pancreatic tumors: A preliminary result
- 22 December 2012
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 27 (3) , 225-232
Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma
A multicenter trial is currently underway using FDG-PET/CT to evaluate diffuse large B cell lymphoma in Japan (JSCT NHL10). Standardization of the image quality between the participating centers is a fundamental aspect of the study. Within the framework of JSCT NHL10, standardization of the image quality was attempted by optimizing the acquisition and reconstruction conditions using mid-therapy FDG-PET/CT for diffuse large B cell lymphoma. This report describes the procedures and results of this attempt. The acquisition protocols and imaging quality were initially determined at each center and again after modification. The image quality was based on performance with an 18F-filled National Electrical Manufacturers Association standards body phantom. We determined that the acquisition duration and reconstruction parameters of each scanner evaluated were in compliance with the Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0 (the Guideline) based on the results of the phantom experiments performed by the Core Laboratory. A total of 18 centers (19 scanners) participated in this trial. The center’s default protocol was unchanged for 9 scanners (47.4 %) and changed for 10 scanners (52.6 %). Both acquisition duration and reconstruction parameters were changed in 3 (15.8 %) of 10 scanners and the acquisition duration alone was changed in 7 (36.8 %) scanners. Also, the accuracy of the standardized uptake value (SUV) was evaluated with the acceptable level 1.0 ± 0.1, resulting in readjustment and recalibration in 2 scanners (10.5 %), which were confirmed to attain the acceptable accuracy after the required readjustment. As of August 2012, 21 patients have undergone an FDG-PET/CT examination under the acquisition protocols determined by the Core Laboratory. Evaluation of the image quality using several physical parameters confirmed that the accumulated data were of sufficient quality. Optimization of the acquisition protocol, in compliance with the guideline, was successfully achieved by the Core Laboratory in the framework of JSCT NHL10 to accumulate equivalent quality data across multiple centers. The progress of the trial was greatly facilitated by support from the Japan Society of Nuclear Medicine Working Group for Investigation of Response Evaluation Criteria in Malignant Tumors Using Standardized PET/CT (Principal Investigator: Ukihide Tateishi, MD., PhD).
- 22 December 2012
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 27 (3) , 225-232
Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma
A multicenter trial is currently underway using FDG-PET/CT to evaluate diffuse large B cell lymphoma in Japan (JSCT NHL10). Standardization of the image quality between the participating centers is a fundamental aspect of the study. Within the framework of JSCT NHL10, standardization of the image quality was attempted by optimizing the acquisition and reconstruction conditions using mid-therapy FDG-PET/CT for diffuse large B cell lymphoma. This report describes the procedures and results of this attempt. The acquisition protocols and imaging quality were initially determined at each center and again after modification. The image quality was based on performance with an 18F-filled National Electrical Manufacturers Association standards body phantom. We determined that the acquisition duration and reconstruction parameters of each scanner evaluated were in compliance with the Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0 (the Guideline) based on the results of the phantom experiments performed by the Core Laboratory. A total of 18 centers (19 scanners) participated in this trial. The center’s default protocol was unchanged for 9 scanners (47.4 %) and changed for 10 scanners (52.6 %). Both acquisition duration and reconstruction parameters were changed in 3 (15.8 %) of 10 scanners and the acquisition duration alone was changed in 7 (36.8 %) scanners. Also, the accuracy of the standardized uptake value (SUV) was evaluated with the acceptable level 1.0 ± 0.1, resulting in readjustment and recalibration in 2 scanners (10.5 %), which were confirmed to attain the acceptable accuracy after the required readjustment. As of August 2012, 21 patients have undergone an FDG-PET/CT examination under the acquisition protocols determined by the Core Laboratory. Evaluation of the image quality using several physical parameters confirmed that the accumulated data were of sufficient quality. Optimization of the acquisition protocol, in compliance with the guideline, was successfully achieved by the Core Laboratory in the framework of JSCT NHL10 to accumulate equivalent quality data across multiple centers. The progress of the trial was greatly facilitated by support from the Japan Society of Nuclear Medicine Working Group for Investigation of Response Evaluation Criteria in Malignant Tumors Using Standardized PET/CT (Principal Investigator: Ukihide Tateishi, MD., PhD).
- 5 November 2012
- Published by Springer Nature
- p. 107-119
Artifacts in FDG PET and PET/CT